We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App




Vircell Showcases Its Powerful Automation System and Immunoassay Testing Kits at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: VirClia® Lotus (Photo courtesy of VIRCLIA)
Image: VirClia® Lotus (Photo courtesy of VIRCLIA)
Vircell (Granada, Spain) exhibited its powerful automation system and immunoassay testing kits at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany.

Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.

At MEDICA 2021, Vircell presented VIRCLIA, its powerful automation system with a built-in reader, intelligent racks and intuitive software. The VIRCLIA automation system offers 192 patient sample positions and fully-automated reader options (EIA or CLIA+EIA). It features a probe-mounted camera for real-time process monitoring and remote diagnostics, along with a built-in barcode reader for streamlined loading and lower sample tracking errors.

Among the immunoassay testing kits showcased by Vircell at the event was the Chlamydia ELISA indirect immunoenzyme assay to test antibodies against chlamydia in human serum/plasma which is suitable for automated ELISA systems. Vircell also highlighted Pneumobact IFA, an indirect immunofluorescent assay kit to simultaneously test IgG or IgM antibodies against the main ethiological bacterial agents causing respiratory tract infections: Legionella pneumophila sero group 1, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Chlamydophila psittaci. The kit enables simultaneous detection of the main bacteria causing atypical pneumonia and easy results reading.

Related Links:
Vircell

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.